BioNTech SE (BVMF:B1NT34)
Brazil · Delayed Price · Currency is BRL 28.92
-0.24 (-0.82%)
At close: Jun 26, 2026
BioNTech SE Employees
BioNTech SE had 7,807 employees as of December 31, 2025. The number of employees increased by 1,035 or 15.28% compared to the previous year.
Employees
7,807
Change (1Y)
1,035
Growth (1Y)
15.28%
Revenue / Employee
2.16M BRL
Profits / Employee
-964.76K BRL
Market Cap
123.66B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 7,807 | 1,035 | 15.28% |
| Dec 31, 2024 | 6,772 | 639 | 10.42% |
| Dec 31, 2023 | 6,133 | 1,603 | 35.39% |
| Dec 31, 2022 | 4,530 | 1,448 | 46.98% |
| Dec 31, 2021 | 3,082 | 1,141 | 58.78% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Raia Drogasil | 75,190 |
| Fleury | 29,000 |
| Empreendimentos Pague Menos | 28,316 |
| Diagnósticos da América | 26,255 |
| Dimed S.A. Distribuidora de Medicamentos | 11,282 |
| Hypera | 10,564 |
| Blau Farmacêutica | 1,900 |
BioNTech SE News
- 13 days ago - Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO - Reuters
- 4 weeks ago - BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial - TheFly
- 4 weeks ago - Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewsWire
- 4 weeks ago - This Biotech's Cancer Portfolio Could End Its Rough Patch - Barrons
- 4 weeks ago - BioNTech upgraded to Buy from Neutral at UBS - TheFly
- 5 weeks ago - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 5 weeks ago - Bernstein starts BioNTech at Market Perform, sees high registration risk - TheFly
- 5 weeks ago - BioNTech initiated with a Market Perform at Bernstein - TheFly